Communicative reprogramming non-curative hepatocellular carcinoma with low-dose metronomic chemotherapy, COX-2 inhibitor and PPAR-gamma agonist: a phase II trial

Systemic therapy for advanced hepatocellular carcinoma (HCC) is still challenging. A biomodulatory therapy approach targeting the communicative infrastructure of HCC, including metronomic low-dose chemotherapy with capecitabine, pioglitazone and rofecoxib, has been evaluated in patients with non-cur...

Descripción completa

Detalles Bibliográficos
Autores principales: Walter, I., Schulz, U., Vogelhuber, M., Wiedmann, K., Endlicher, E., Klebl, F., Andreesen, R., Herr, W., Ghibelli, L., Hackl, C., Wiest, R., Reichle, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668342/
https://www.ncbi.nlm.nih.gov/pubmed/29098441
http://dx.doi.org/10.1007/s12032-017-1040-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668342/
https://www.ncbi.nlm.nih.gov/pubmed/29098441
http://dx.doi.org/10.1007/s12032-017-1040-0

Ejemplares similares